Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,420 across all filing types
Latest filing 2025-12-17 Regulatory Filings
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Hull Investments & PAC
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. It details the allotment of shares pursuant to a composite scheme of amalgamation approved by the National Company Law Tribunal. The document includes specifics about share allotment, shareholding percentages pre- and post-transaction, and the exemption from open offer obligations under SEBI regulations. It is a regulatory disclosure related to a substantial acquisition of shares and takeover exemption, not a financial report, earnings release, or management discussion. The document is a formal regulatory filing notifying stock exchanges about the acquisition and exemption status, fitting the category of Regulatory Filings (RNS). The document length (8721 characters) and content confirm it is not a brief announcement or a full report but a detailed regulatory disclosure.
2025-12-17 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Hull Investments & PAC
Major Shareholding Notification Classification · 100% confidence The document is a detailed disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. It reports the acquisition of shares and changes in shareholding percentages following a composite scheme of amalgamation approved by the National Company Law Tribunal. The content focuses on shareholding changes, acquisition details, and compliance with takeover regulations. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other financial report type, but a regulatory disclosure about shareholding changes due to a merger/amalgamation event.
2025-12-17 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Hull Investments & PAC
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. It details the acquisition of shares by CA Hull Investments in Sequent Scientific Limited pursuant to a composite scheme of amalgamation approved by the National Company Law Tribunal. The document includes specifics about share allotment, shareholding percentages before and after acquisition, and compliance with SEBI takeover regulations. This type of filing is a notification of a major shareholding change due to acquisition/allotment, which fits the category of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or other financial report, but a regulatory disclosure about shareholding changes.
2025-12-17 English
Update on scheme of Arrangement
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Sequent Scientific Limited regarding the outcome of a board meeting held on December 16, 2025. It includes information about the approval of allotment of equity shares and warrants pursuant to a composite scheme of amalgamation, changes in management including appointments and resignations of key personnel, and other consequential matters related to the scheme's effectiveness. The document references regulatory compliance under SEBI Listing Regulations and includes annexures with detailed disclosures about the new appointments. The content focuses on corporate actions, share allotments, and management changes rather than financial results, earnings, or audit information. Therefore, the document is best classified as a Board/Management Information filing, as it primarily announces changes in the company's board of directors and senior management along with related corporate actions.
2025-12-16 English
Scheme of Arrangement
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Sequent Scientific Limited dated December 16, 2025, regarding the outcome of a board meeting. It includes information about the approval of allotment of equity shares and warrants pursuant to a composite scheme of amalgamation, changes in management including appointments and resignations of key personnel, and other consequential matters related to the scheme's effectiveness. The document references regulatory compliance under SEBI Listing Regulations and includes annexures with detailed disclosures about the new appointments. The content focuses on corporate actions such as share allotment and management changes rather than financial results, earnings, or audit information. It is not a full financial report or earnings release but an official announcement of board decisions and management changes. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it primarily announces changes in the company's board of directors and senior management along with related corporate actions.
2025-12-16 English
Change in Management
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Sequent Scientific Limited dated December 16, 2025, regarding the outcome of a board meeting. It includes information about the approval of allotment of equity shares and warrants pursuant to a composite scheme of amalgamation, changes in management including appointments and resignations of key personnel, and other consequential matters related to the scheme's effectiveness. The document references regulatory compliance under SEBI Listing Regulations and includes annexures with detailed disclosures about the new appointments. The content focuses on corporate actions such as share allotment and management changes rather than financial results, earnings, or audit information. It is not a full financial report, earnings release, or audit report. The primary focus is on management changes and corporate restructuring. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it announces changes in the company's board of directors and senior management along with related corporate actions.
2025-12-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.